F2G Biotech said it will be spending most of the assets to push forward pivotal clinical trials of its lead compound Olorofim (F901318), a Phase IIb orphan drug against pulmonal Aspergillus infections. Olorofim belongs to a new class of fungistatics called orotomides that target the enzyme dihydroorotate dehydrogenase (DHODH) in the de novo pyrimidine biosynthesis pathway. The compound has been shown to inhibit germination and growth in vitro. According to the Manchester-based company, prolonged exposure is fungicidal through hyphal swelling followed by cell lysis.
In Europe, more than 90,000 people per year suffer from invasive aspergilosis, which can be currently treated with amphotericin, caspofungin, isavucononazole, itraconazole, posaconazole and voriconazole. However, olorofim has been shown to be effective against infections resistant to azole antifungal medicines. Antimicrobial resistance ()AMR) against the current three classes of antifungals is a growing concern.